http://purl.org/np/RAwEAFJsLuzZ-2dMB67LDWGeCFsAEvposhL77ZKlWmQXY#Head http://purl.org/np/RAwEAFJsLuzZ-2dMB67LDWGeCFsAEvposhL77ZKlWmQXY http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAwEAFJsLuzZ-2dMB67LDWGeCFsAEvposhL77ZKlWmQXY#assertion http://purl.org/np/RAwEAFJsLuzZ-2dMB67LDWGeCFsAEvposhL77ZKlWmQXY http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAwEAFJsLuzZ-2dMB67LDWGeCFsAEvposhL77ZKlWmQXY#provenance http://purl.org/np/RAwEAFJsLuzZ-2dMB67LDWGeCFsAEvposhL77ZKlWmQXY http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAwEAFJsLuzZ-2dMB67LDWGeCFsAEvposhL77ZKlWmQXY#pubinfo http://purl.org/np/RAwEAFJsLuzZ-2dMB67LDWGeCFsAEvposhL77ZKlWmQXY http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAwEAFJsLuzZ-2dMB67LDWGeCFsAEvposhL77ZKlWmQXY#assertion http://purl.obolibrary.org/obo/DOID_769 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAwEAFJsLuzZ-2dMB67LDWGeCFsAEvposhL77ZKlWmQXY#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_769 http://purl.org/np/RAwEAFJsLuzZ-2dMB67LDWGeCFsAEvposhL77ZKlWmQXY#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAwEAFJsLuzZ-2dMB67LDWGeCFsAEvposhL77ZKlWmQXY#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB09077 http://purl.org/np/RAwEAFJsLuzZ-2dMB67LDWGeCFsAEvposhL77ZKlWmQXY#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAwEAFJsLuzZ-2dMB67LDWGeCFsAEvposhL77ZKlWmQXY#association http://www.w3.org/2000/01/rdf-schema#label unituxin dinutuximab is indicated in combination with granulocyte macrophage colony stimulating factor gm csf interleukin 2 il 2 and 13 cis retinoic acid ra for the treatment of pediatric patients with high risk neuroblastoma who achieve at least a partial response to prior first line multiagent multimodality therapy see clinical studies 14 unituxin is a gd2 binding monoclonal antibody indicated in combination with granulocyte macrophage colony stimulating factor gm csf interleukin 2 il 2 and 13 cis retinoic acid ra for the treatment of pediatric patients with high risk neuroblastoma who achieve at least a partial response to prior first line multiagent multimodality therapy 1 http://purl.org/np/RAwEAFJsLuzZ-2dMB67LDWGeCFsAEvposhL77ZKlWmQXY#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAwEAFJsLuzZ-2dMB67LDWGeCFsAEvposhL77ZKlWmQXY#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAwEAFJsLuzZ-2dMB67LDWGeCFsAEvposhL77ZKlWmQXY#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB09077 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAwEAFJsLuzZ-2dMB67LDWGeCFsAEvposhL77ZKlWmQXY#provenance http://purl.org/np/RAwEAFJsLuzZ-2dMB67LDWGeCFsAEvposhL77ZKlWmQXY#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAwEAFJsLuzZ-2dMB67LDWGeCFsAEvposhL77ZKlWmQXY#pubinfo http://purl.org/np/RAwEAFJsLuzZ-2dMB67LDWGeCFsAEvposhL77ZKlWmQXY#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAwEAFJsLuzZ-2dMB67LDWGeCFsAEvposhL77ZKlWmQXY#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAwEAFJsLuzZ-2dMB67LDWGeCFsAEvposhL77ZKlWmQXY#sig http://purl.org/nanopub/x/hasSignature W3bkHC2cpiVGhP++NBsvHvoT2oxPuxwClvXMagZCiSOlsgzJV0o/fgNVSdstjazVxJhMRGD1Cm1DD+rkgdeMhK9q0LjDe2s4JoUTb6JVhII9l84JyBPfXX1z32Lum+oj3xOiDb+n+DzVI3d1TUzo5Iw2tsS5xMyLTrydGFR/2IE= http://purl.org/np/RAwEAFJsLuzZ-2dMB67LDWGeCFsAEvposhL77ZKlWmQXY#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAwEAFJsLuzZ-2dMB67LDWGeCFsAEvposhL77ZKlWmQXY http://purl.org/np/RAwEAFJsLuzZ-2dMB67LDWGeCFsAEvposhL77ZKlWmQXY http://purl.org/dc/terms/created 2021-07-03T14:54:35.900+02:00 http://purl.org/np/RAwEAFJsLuzZ-2dMB67LDWGeCFsAEvposhL77ZKlWmQXY http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAwEAFJsLuzZ-2dMB67LDWGeCFsAEvposhL77ZKlWmQXY https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAwEAFJsLuzZ-2dMB67LDWGeCFsAEvposhL77ZKlWmQXY https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAwEAFJsLuzZ-2dMB67LDWGeCFsAEvposhL77ZKlWmQXY https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs